Discovering & Developing a New Era of Cardiometabolic Therapeutics

The obesity therapeutics landscape is undergoing a radical expansion, fueled by groundbreaking late-stage trials for Novo Nordisk's amycretin and Metsera's exciting early data for its amylin-targeting shot. Underscored by new insights into Eli Lilly's tirzepatide's cardiovascular benefits, the field is witnessing a paradigm shift beyond GLP-1s to novel mechanisms, combination therapies, and oral formulations. This new era of innovation promises wider accessibility and improved patient outcomes, making the 2nd Innovation in Obesity Therapeutics Summit the essential forum for accelerating the next wave of treatment. 

This year, we're diving deep into game-changing potential of novel mechanisms of action, muscle-preserving strategies, and multi-agonist therapies. Hear from the titans of the pharmaceutical industry, including Novo Nordisk, Eli Lilly and Boehringer Ingelheim, as well as innovative biotechs like Veru, Supercede Therapeutics, and Rivus Pharmaceuticals, who will share their groundbreaking research and strategies. The pressure is on to continue work on developing best-in-class treatments that transform patient lives. 

Don't miss this pivotal opportunity to network with 60+ leading scientists and drug development experts in the field of obesity, forge crucial collaborations, and be part of the solution. The future of obesity therapeutics is being written now – be a part of it!